Quick FactsAn estimated 60,000 cases of MDR-TB a year are not responding to standard TB drug treatment
Carol A. Nacy, Ph.D.
Co-Founder, Chief Executive Officer, Chairman of the Board of Directors
Dr. Nacy co-founded our company in 1997 and has served as our CEO and Chairman of the Board since 1999. Prior to Sequella, Dr. Nacy served during 1997 and 1998 as Chief Scientific Officer (CSO) for Anergen, Inc. (NASDAQ: ANRG), a California company acquired by Corixa Corporation in December 1998. From 1993 through 1997, Dr. Nacy was Executive Vice President and CSO at EntreMed, Inc. (NASDAQ: ENMD) and participated in its successful initial public offering in June 1996. Previously, Dr. Nacy was Career Scientist (GS-15) at the Walter Reed Army Institute of Research, Washington, DC. Dr. Nacy currently serves on board of directors of companies and non-profit agencies.
Leo Einck, Ph.D.
Co-Founder, Director, and Chief Scientific Officer
Dr. Einck, a co-founder of our company, joined Sequella as President in 1998. He started and managed several biotechnology companies, including Director of Sponsored Research, Vice-President for Extramural Programs, and then the Vice President for Research Operations at EntreMed (NASDAQ: ENMD) from 1993-1998 and Chief Operating Officer of HemispheRx Biopharma (NYSE: HEB, 1985-1993). Prior to his business experience, Dr. Einck was a molecular biologist at the National Cancer Institute of the NIH.
Mark Rampy, Ph.D., MBA
Chief Business Officer.
Dr. Rampy has over 20 years of industry experience. Prior to Sequella, he was CEO of several start-ups (Theraly Pharmaceuticals and CohBar, Inc), VP Business Development Biologics and Specialty Products, Teva Pharmaceuticals (NYSE: TEVA), Founder and Chief Business Officer of CoGenesys, Inc. (CGS) a company spun out of Human Genome Sciences, Inc. (NASDAQ: HGSI) that was later acquired by Teva. Prior to CGS, he was with HGSI for 11 years, where he held positions of increasing responsibility in R&D and Business Development, the most senior of which was Head of Business Development. Dr. Rampy has a Ph.D. in Pharmacology from the University of Michigan and MBA from Georgetown University.
Lisa Beth Ferstenberg, M.D.
Dr. Ferstenberg has spent over 30 years in biopharmaceutical development and has a depth of experience in clinical trials purposed for regulatory submissions and drug approvals. Her areas of specialization include oncology, immunology, vaccines, and infectious diseases of global importance such as TB, HIV, malaria and others. She has a particular focus on pharmacovigilance for developing and marketed drugs and has been trained in MedDRA coding of terms. Dr. Ferstenberg has held senior executive positions in several early stage pharmaceutical and biotechnology companies, and is a serial entrepreneur with a history of successful fund-raising efforts and exits.
David Mc Neeley, M.D., M.P.H.T.M,
Senior Vice President, Global Medical Programs
Dr. Mc Neeley received his medical degree and a master’s degree in public health and tropical medicine from Tulane University. He completed a fellowship in pediatric infectious diseases at Weill Cornell Medical College. He was in active clinical practice for over 20 years, which included extensive experience internationally and as a member of the faculty at Weill Cornell Medical College in New York City. He has spent the last 12 years working in clinical research and development in the pharmaceutical industry (Johnson & Johnson and Novartis), where he has concentrated his activities on infectious diseases and neglected tropical diseases (pediatric bacterial infections, tuberculosis, human immunodeficiency virus, hepatitis B virus, malaria and other parasitic diseases).